Key Takeaways for Hims & Hers Health Stock as of August 2026
- CEO Rebuttal Rally: HIMS stock jumped 14% Wednesday after Dudum’s CNBC pushback on the FTC lawsuit.
- Pricing Reset Pledge: Dudum told CNBC that out-of-pocket GLP-1 costs could fall to $40 to $50 a month from $150 to $200, a promise investors read as margin relief following the FTC-driven selloff.
- Street Stuck at Hold: The current split runs 1 buy, 2 outperforms, 12 holds, 1 no opinion, and 1 underperform, and the $31 mean target sits almost exactly on Wednesday’s $31 close.
- Model Sees Little Left: TIKR’s mid-case model values HIMS stock at $36 by December 2030, implying 14% total return and 3% annualized over 4.4 years.
A stock that just jumped 14% still carries only 1 buy rating and 12 holds. See the full ratings history on TIKR for free →
Why HIMS Stock Jumped 14% as Dudum Countered the FTC
Hims & Hers Health (HIMS) stock jumped 14% on Wednesday, August 19, closing at $31 after CEO Andrew Dudum used a CNBC interview to push back hard on the Federal Trade Commission’s lawsuit and lay out a pricing plan that eases the market’s biggest worry about the business: margins.
The rally reversed three weeks of selling. The FTC sued Hims & Hers on July 29, alleging the company shared users’ health data with Meta and Snap despite promising privacy, and the stock fell nearly 14% that day to $25. Q2 earnings on August 10 didn’t help. Revenue grew 40% year over year to $753 million and beat estimates, and the company raised its full-year revenue guidance to $3.1 billion to $3.3 billion. But the quarter swung to an $86.3 million net loss, and gross margin fell 12 points to 64% as the mix shifted toward branded weight-loss drugs. Shares fell further in the days that followed as analysts flagged the margin compression.
Dudum’s Tuesday interview, which aired on CNBC and drew wide coverage Wednesday, changed the tone. He called the FTC’s decision to sue “more of a headline than a real agreement here,” pointing to nearly three years of cooperation with the agency before litigation began. He then told viewers that out-of-pocket GLP-1 costs, currently $150 to $200 a month for cash-paying patients, could fall to $40 to $50 as the branded drug supply chain matures. That’s the same playbook Hims & Hers ran in sexual health and hair loss, where lower prices expanded the customer base and improved retention.
The CEO also detailed the company’s shift toward proprietary AI infrastructure rather than third-party vendors, arguing the “closed loop data” inside a healthcare platform like Hims & Hers is the real asset. None of it resolves the FTC case, and margins haven’t recovered. But it gave investors a reason to treat the July and August selloff as overdone rather than the start of a structural problem.
Dudum’s CNBC pushback on the FTC lawsuit sent HIMS stock up. See what that does to Hims & Hers margins on TIKR for free →
HIMS Stock Street Targets Show a Year of Eroding Conviction
HIMS stock draws ratings from 1 buy, 2 outperforms, 12 holds, 1 no opinion, and 1 underperform, and 13 analysts carry live price targets. The mean target of $31 sits almost exactly on top of Wednesday’s $31 close, a gap thin enough that the Street isn’t calling the rally either cheap or expensive.
That flat reading follows a year of the target lagging the stock rather than leading it. In June 2025, the $50 mean target sat right on the $50 close. By December, the stock had crashed to $32 while the target was still stuck at $45, 38% above the price, evidence the Street hadn’t caught down yet. Targets kept falling through March, but when the stock ripped back to $35 by June 2026, the mean target only recovered to $27, flipping the gap to 23% below the price, the first time in the table analysts sat behind the stock instead of ahead of it. Wednesday’s rally erased that gap in a single session.
Buy ratings fell from 4 to 1 over the past year while holds climbed from 7 to 12, and sell ratings that used to number 1 or 2 have disappeared from the table entirely. Analysts aren’t leaving HIMS stock. They’re just less willing to commit to a direction, and Dudum’s CNBC comments landed on a Street that had already downgraded its conviction well before Wednesday.
TIKR Values HIMS Stock at $36, Pricing In a Modest Recovery
TIKR’s mid-case model values Hims & Hers Health stock at $36 by December 2030, implying 14% total return from the current price of $31, or 3% annualized over the next 4.4 years.
That’s a thin return for a stock that just moved 14% in a single session, and it puts HIMS stock closer to a bond-like holding than a growth re-rating story over the model’s time horizon.
The gap between Wednesday’s rally and the model’s modest target traces straight back to Sections 1 and 2. Dudum’s promised $40 to $50 GLP-1 pricing and the AI payback he described could widen margins beyond what the model assumes, but gross margin has already contracted 12 points and the FTC case remains open. The Street’s mean target sitting right on the current price backs the model’s read: Wednesday closed a valuation gap that had opened since June, it didn’t create a new one.
TIKR’s model puts HIMS stock at $36 with a 3% annualized return through 2030. Run your own numbers on TIKR for free →
Should You Invest in Hims & Hers Health, Inc.?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up Hims & Hers Health, Inc. stock and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track Hims & Hers Health, Inc. alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Access Professional Tools to Analyze HIMS stock on TIKR for Free →
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
